Benjamin Diaczok1, Girish Nair2, Chun-Hui Lin3, James H Paxton4, Amr Abbas5, Greg Barkley6, Brian O'Neil4, William O'Neil7, Kirit Patel8, Matthew Sims9, Laila Poisson3, Anupam Ashutosh Sule1. 1. Department of Internal Medicine, St. Joseph Mercy Oakland, Pontiac, USA. 2. Department of Pulmonary and Critical Care, Beaumont Health System, Royal Oak, USA. 3. Department of Public Health Sciences, Henry Ford Health System, Detroit, USA. 4. Department of Emergency Medicine, Wayne State University, Detroit, USA. 5. Department of Cardiology, Beaumont Health System, Sterling Heights, USA. 6. Department of Neurology, Henry Ford Health System, Detroit, USA. 7. Department of Cardiology, Henry Ford Health System, Detroit, USA. 8. Department of Cardiology, St. Joseph Mercy Oakland, Pontiac, USA. 9. Department of Infectious Diseases, Beaumont Health System, Royal Oak, USA.
Abstract
Introduction: We wanted to characterize the evolution of the COVID-19 pandemic in a typical metropolitan area. Methods: Data were extracted from the Detroit COVID-19 Consortium database for hospitalized COVID-19 patients treated in Southeast Michigan over the 12-month period from March 2020 to February 2021. Demographic and outcomes data were compared to CDC data. Results: A total of 4,775 patients were enrolled during the study period. We divided the pandemic into three phases: Phase-1 (Spring Surge); Phase-2 (Summer Lull); and Phase-3 (Fall Spike). Changes in hydroxychloroquine, remdesivir, corticosteroid, antibiotic and anticoagulant use closely followed publication of landmark studies. Mortality in critically-ill patients decreased significantly from Phase-1 to Phase-3 (60.3% vs. 47.9%, Chisq p=0.0110). Monthly mortality of all hospitalized patients ranged between 14.8% - 21.5% during Phase-1 and 9.7 to 13.4% during Phase 3 (NS). Discussion: The COVID-19 pandemic presented in three unique phases in Southeast Michigan. Medical systems rapidly modified treatment plans, often preceding CDC and NIH recommendations. Despite improved treatment regimens, intubation rates and mortality for hospitalized patients remained elevated. Conclusion: Preventive measures aimed at reducing hospitalizations for COVID-19 should be emphasized.
Introduction: We wanted to characterize the evolution of the COVID-19 pandemic in a typical metropolitan area. Methods: Data were extracted from the Detroit COVID-19 Consortium database for hospitalized COVID-19 patients treated in Southeast Michigan over the 12-month period from March 2020 to February 2021. Demographic and outcomes data were compared to CDC data. Results: A total of 4,775 patients were enrolled during the study period. We divided the pandemic into three phases: Phase-1 (Spring Surge); Phase-2 (Summer Lull); and Phase-3 (Fall Spike). Changes in hydroxychloroquine, remdesivir, corticosteroid, antibiotic and anticoagulant use closely followed publication of landmark studies. Mortality in critically-ill patients decreased significantly from Phase-1 to Phase-3 (60.3% vs. 47.9%, Chisq p=0.0110). Monthly mortality of all hospitalized patients ranged between 14.8% - 21.5% during Phase-1 and 9.7 to 13.4% during Phase 3 (NS). Discussion: The COVID-19 pandemic presented in three unique phases in Southeast Michigan. Medical systems rapidly modified treatment plans, often preceding CDC and NIH recommendations. Despite improved treatment regimens, intubation rates and mortality for hospitalized patients remained elevated. Conclusion: Preventive measures aimed at reducing hospitalizations for COVID-19 should be emphasized.
Authors: Benjamin Gallo Marin; Ghazal Aghagoli; Katya Lavine; Lanbo Yang; Emily J Siff; Silvia S Chiang; Thais P Salazar-Mather; Luba Dumenco; Michael C Savaria; Su N Aung; Timothy Flanigan; Ian C Michelow Journal: Rev Med Virol Date: 2020-07-30 Impact factor: 6.989
Authors: John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane Journal: N Engl J Med Date: 2020-10-08 Impact factor: 91.245
Authors: Jun Chen; Danping Liu; Li Liu; Ping Liu; Qingnian Xu; Lu Xia; Yun Ling; Dan Huang; Shuli Song; Dandan Zhang; Zhiping Qian; Tao Li; Yinzhong Shen; Hongzhou Lu Journal: Zhejiang Da Xue Xue Bao Yi Xue Ban Date: 2020-05-25
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Remo H M Furtado; Otavio Berwanger; Henrique A Fonseca; Thiago D Corrêa; Leonardo R Ferraz; Maura G Lapa; Fernando G Zampieri; Viviane C Veiga; Luciano C P Azevedo; Regis G Rosa; Renato D Lopes; Alvaro Avezum; Airton L O Manoel; Felipe M T Piza; Priscilla A Martins; Thiago C Lisboa; Adriano J Pereira; Guilherme B Olivato; Vicente C S Dantas; Eveline P Milan; Otavio C E Gebara; Roberto B Amazonas; Monalisa B Oliveira; Ronaldo V P Soares; Diogo D F Moia; Luciana P A Piano; Kleber Castilho; Roberta G R A P Momesso; Guilherme P P Schettino; Luiz Vicente Rizzo; Ary Serpa Neto; Flávia R Machado; Alexandre B Cavalcanti Journal: Lancet Date: 2020-09-05 Impact factor: 79.321